ClinicalTrials.gg
RecruitingNCT06991257Updated Oct 23, 2026

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

A Phase 2 interventional study of Placebo and Low Dose PF-07328948 in Heart Failure, sponsored by Pfizer. Recruiting at 150 sites in 14 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Oct 23, 2026First site in ArgentinaSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,158 studies in Heart Failure with a site in United States — 347 open to participants now, 438 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
209th of 1,601
620 · median 65
Started
2025
with 107 others
Phase 2
227 of 2,158
26 open now
Primary completion
2028-05
later than 308 of 437 live
Registered
2,020th of 2,158
by date

Among the 2,158 studies in Heart Failure with a site in United States, this one is the 209th largest by planned enrollment of the 1,601 interventional ones that give a count, is one of 108 that started in 2025, is one of 227 in phase 2, reaches primary completion later than 308 of the 437 other live ones, and was the 2,020th registered.

Heart Failure

6,337 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,158 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,158 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).

Read the detailed description

All participants in this study will take either the study medicine (PF-07328948) tablets, or placebo tablets, once daily, by mouth, every day for 36 weeks. The study determines if the study medicine (PF-07328948) is safe and effective compared to placebo in people with heart failure who are already taking standard-of-care medications for heart failure that include sodium-glucose cotransporter 2 (SGLT2) inhibitors. Participants will be involved in this study for about 48 weeks. During this time, participants will visit the study clinic 15 times. In general, 5 of these visits may be performed at home by phone and the other 10 visits will take place at the study site.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart Failure with mildly reduced ejection
  • Heart Failure with preserved ejection fraction
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

This study is seeking participants who are:

Key Inclusion Criteria include:

  • aged 18 years to \< 80 years
  • clinically confirmed to have a diagnosis of heart failure for at least 3 months
  • Class II-IV symptoms
  • greater than 40%
  • Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score \< 85
  • Six-minute walking distance greater than 75 meters

Key Exclusion Criteria include:

  • Type 1 diabetes mellitus, liver cirrhosis or any condition that can possibly affect how the medicine is absorbed into the body.
  • Major surgery scheduled for the duration of the study, affecting walking ability in the opinion of the study doctor.
  • History of heart transplantation, or currently listed for a heart transplant, or current planned use of IV vasodilators and/ or inotropes
  • Prior intolerance/known to an SGLT2 inhibitor or to an SGLT2 inhibitor
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
620 participants (estimated)

Study arms

  • Placebo comparator
    ARM 1

    Placebo Participants will receive Placebo for up to 36 weeks

    Drug: Placebo

  • Experimental
    ARM 2

    Low dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks

    Drug: Low Dose PF-07328948

  • Experimental
    ARM 3

    Medium dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks

    Drug: Medium Dose PF-07328948

  • Experimental
    ARM 4

    High dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks

    Drug: High Dose PF-07328948

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Clinical Events

    Adjudicated cardiovascular death and worsening heart failure events through 36 weeks.

    Time frame: over 36 weeks

  2. Change From Baseline in 6-Minute Walk Test (6MWD)

    A submaximal exercise test that measures the distance the participant can walk within prescribed time of 6 minutes. Participants are asked to perform the test at a pace comfortable to them with as many breaks as needed. The total distance walked is recorded.

    Time frame: Baseline, week 36 post-dose

  3. Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Total Symptom Score (KCCQ-23 TSS)

    KCCQ is a 23-item heart-failure specific questionnaire quantified into the following scores: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life, and self-efficacy, total symptom score, overall summary score, and clinical summary score. To facilitate interpretation, all scores are presented on a scale of 0 to 100 points, with lower scores indicating more severe symptoms and/or limitations, and a score of 100 indicating no symptoms, no limitations, and excellent quality of life.

    Time frame: Baseline, week 36

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE that, at any dose, results in 1 or more of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 40 that were absent before treatment or that worsened relative to pre-treatment state. AEs include both serious and non-serious adverse events.

    Time frame: Baseline, up to week 40

  2. Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Symptom Score (KCCQ-23 TSS) and physical limitation in participants taking PF-07328948 vs. placebo on HF disease-specific health status related to HFmrEF/HFpEF.

    KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). Two summary scores are also calculated: Clinical Summary (calculated as mean of Physical limitation and Total symptom scores) and Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores). Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status.

    Time frame: Baseline, week 36

  3. Change From Baseline in 6-minute walk test distance (6MWD) in participants taking PF-07328948 vs. placebo on HF disease-specific health status related to HFmrEF/HFpEF.

    A submaximal exercise test that measures the distance the participant can walk within prescribed time of 6 minutes. Participants are asked to perform the test at a pace comfortable to them with as many breaks as needed. The total distance walked is recorded.

    Time frame: Baseline, week 36

  4. CPET Substudy) : Change From Baseline in Peak Oxygen Consumption (pVO2) at Week 36

    Cardiopulmonary exercise testing

    Time frame: Baseline, Week 36

  5. Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week 36

    NT-proBNP is a biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).

    Time frame: Baseline, Week 36

  6. Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall clinical symptom Score (KCCQ-23 CSS) and physical limitation) in participants taking PF-07328948 vs. placebo on HF disease-specific health status related to HFmrEF/HFpEF.

    KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). Two summary scores are also calculated: Clinical Summary (calculated as mean of Physical limitation and Total symptom scores) and Overall Summary (calculated as mean of Physical limitation, social limitation, Total symptoms, and Quality of life scores). Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status.

    Time frame: Baseline, week 36

07

Study locations

141 of 150 sites recruiting

Showing the first 100 of 150 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2028, 34 months after the start.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 34 months is above that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Nov 2027 → May 2028 and completion Dec 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
May 27, 2025
StartActual
Jun 19, 2025
Primary completionEst.
May 8, 2028was Nov 2027
CompletionEst.
Jun 5, 2028was Dec 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 4 sites removed — first site in Argentina. 10 sites changed recruiting status (7 now recruiting, 3 now active, not recruiting)
Show 10 sites
  • National Heart Institute · Beverly Hills, United StatesRecruiting→Active, not recruiting
  • Orange County Research Center · Lake Forest, United StatesRecruiting→Active, not recruiting
  • Chesapeake Cardiac Care · Bowie, United StatesNot yet recruiting→Recruiting
  • Flourish Research - Bowie · Bowie, United StatesNot yet recruiting→Recruiting
  • Richmond Clinical Trials · Richmond, CanadaRecruiting→Active, not recruiting
  • The First Hospital of Hebei Medical University · Shijiazhuang, ChinaNot yet recruiting→Recruiting
  • China-Japan Union Hospital · Changchun, ChinaNot yet recruiting→Recruiting
  • Zhongshan Hospital,Fudan University · Shanghai, ChinaNot yet recruiting→Recruiting
  • CHUS - Hospital Clinico Universitario · Santiago de Compostela, SpainNot yet recruiting→Recruiting
  • Hospital Universitari de Bellvitge · L'Hospitalet de Llobregat, SpainNot yet recruiting→Recruiting
Show 12 added (7 Argentina, 3 United States, 1 Spain, 1 United Kingdom)
  • DBC Research USA, Corp · Pembroke Pines, United States
  • Texas Health Physicians Group · Fort Worth, United States
  • Texas Health Research & Education Institute - Fort Worth · Fort Worth, United States
  • DIM Clínica Privada · Ramos Mejía, Argentina
  • Corporación Médica San Martín · San Martín, Argentina
  • Sanatorio Británico · Rosario, Argentina
  • CEMEDIC · CABA, Argentina
  • Hospital Privado Universitario de Córdoba · Córdoba, Argentina
  • Instituto Médico DAMIC · Córdoba, Argentina
  • Centro de Investigaciones Clinicas del Litoral · Santa Fe, Argentina
  • Hospital Universitario Reina Sofia · Córdoba, Spain
  • Northern General Hospital · Sheffield, United Kingdom
Show 4 removed
  • FWD Clinical Research · Boca Raton, United States
  • L2IP - Instituto de Pesquisas Clínicas · Brasília, Brazil
  • CMed Rehabilitacios es Diagnosztikai Kozpont · Székesfehérvár, Hungary
  • Toho University Sakura Medical Center · Sakura, Japan
Oct 23, 2026
Primary completion
Nov 16, 2027→May 8, 2028
Oct 23, 2026
Study completion
Dec 14, 2027→Jun 5, 2028
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    12 sites added, 4 sites removed — first site in Argentina. 10 sites changed recruiting status (7 now recruiting, 3 now active, not recruiting)
    Show 10 sites
    • National Heart Institute · Beverly Hills, United StatesRecruiting→Active, not recruiting
    • Orange County Research Center · Lake Forest, United StatesRecruiting→Active, not recruiting
    • Chesapeake Cardiac Care · Bowie, United StatesNot yet recruiting→Recruiting
    • Flourish Research - Bowie · Bowie, United StatesNot yet recruiting→Recruiting
    • Richmond Clinical Trials · Richmond, CanadaRecruiting→Active, not recruiting
    • The First Hospital of Hebei Medical University · Shijiazhuang, ChinaNot yet recruiting→Recruiting
    • China-Japan Union Hospital · Changchun, ChinaNot yet recruiting→Recruiting
    • Zhongshan Hospital,Fudan University · Shanghai, ChinaNot yet recruiting→Recruiting
    • CHUS - Hospital Clinico Universitario · Santiago de Compostela, SpainNot yet recruiting→Recruiting
    • Hospital Universitari de Bellvitge · L'Hospitalet de Llobregat, SpainNot yet recruiting→Recruiting
    Show 12 added (7 Argentina, 3 United States, 1 Spain, 1 United Kingdom)
    • DBC Research USA, Corp · Pembroke Pines, United States
    • Texas Health Physicians Group · Fort Worth, United States
    • Texas Health Research & Education Institute - Fort Worth · Fort Worth, United States
    • DIM Clínica Privada · Ramos Mejía, Argentina
    • Corporación Médica San Martín · San Martín, Argentina
    • Sanatorio Británico · Rosario, Argentina
    • CEMEDIC · CABA, Argentina
    • Hospital Privado Universitario de Córdoba · Córdoba, Argentina
    • Instituto Médico DAMIC · Córdoba, Argentina
    • Centro de Investigaciones Clinicas del Litoral · Santa Fe, Argentina
    • Hospital Universitario Reina Sofia · Córdoba, Spain
    • Northern General Hospital · Sheffield, United Kingdom
    Show 4 removed
    • FWD Clinical Research · Boca Raton, United States
    • L2IP - Instituto de Pesquisas Clínicas · Brasília, Brazil
    • CMed Rehabilitacios es Diagnosztikai Kozpont · Székesfehérvár, Hungary
    • Toho University Sakura Medical Center · Sakura, Japan
    Primary completion Nov 16, 2027→May 8, 2028
    Study completion Dec 14, 2027→Jun 5, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06991257
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 27, 2025
Start date
Jun 19, 2025
Primary completion
May 8, 2028 (estimated)
Completion
Jun 5, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-07328948

Start the discussion